New Orphazyme boss will start sales adventure: "It’s all about getting the drug to the market"

The primary objective for Kim Stratton, new CEO of Orphazyme, is to get the company's drug arimocolmal approved and onto the market. To reach this goal, she will use her experience from Shirre and take on a Danish-inspired leadership style.

Kim Stratton, CEO of Orphazyme Photo: Novozymes/ PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles